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Edited by Ga´spa´r Je´kelyAbstract The anticoagulant protein C system regulates the
activity of coagulation factors VIIIa and Va, cofactors in the
activation of factor X and prothrombin, respectively. Protein C
is activated on endothelium by the thrombin–thrombomodulin–
EPCR (endothelial protein C receptor) complex. Activated pro-
tein C (APC)-mediated cleavages of factors VIIIa and Va occur
on negatively charged phospholipid membranes and involve pro-
tein cofactors, protein S and factor V. APC also has anti-inﬂam-
matory and anti-apoptotic activities that involve binding of APC
to EPCR and cleavage of PAR-1 (protease-activated receptor-
1). Genetic defects aﬀecting the protein C system are the most
common risk factors of venous thrombosis. The protein C system
contains multi-domain proteins, the molecular recognition of
which will be reviewed.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Blood coagulation and platelet-dependent primary hemosta-
sis have evolved as important defense mechanisms against
bleeding. The formation of the platelet plug provides the initial
occlusion of the vascular lesion. The coagulation system is
simultaneously activated by tissue factor (TF), which is ex-
posed to blood. Circulating factor VIIa (FVIIa) binds to TF
and the generated FVIIa–TF complex eﬃciently converts fac-
tor IX (FIX) and factor X (FX) to active enzymes FIXa and
FXa. FIXa and FXa take part in multi-molecular enzymatic
complexes, the tenase and prothrombinase complexes, respec-
tively, which propagate the coagulation process [1–4]. These
complexes form on the surface of negatively charged phospho-
lipids, e.g., on activated platelets, and in addition to the en-Abbreviations: APC, activated protein C; AT, antithrombin; CCP,
complement control protein; C4BP, C4b-binding protein; EPCR,
endothelial protein C receptor; EGF, epidermal growth factor; FV,
factor V; Gla, c-carboxy glutamic acid; LamG, laminin G-type; PCI,
protein C inhibitor; PAR-1, protease-activated receptor-1; TAFI,
thrombin activatable ﬁbrinolysis inhibitor; TM, thrombomodulin;
TSR, thrombin-sensitive region
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factor VIII (FVIIIa) in the tenase complex and activated factor
V (FVa) in the prothrombinase complex (Fig. 1). FVIIIa and
FVa derive from circulating high molecular weight precursor
proteins and are converted to their active forms early during
the coagulation by thrombin or FXa [1,4–7]. The tenase com-
plex (FIXa–FVIIIa) activates FX, whereas the prothrombinase
complex (FXa–FVa) converts prothrombin to thrombin. In
the tenase and the prothrombinase complexes, the catalytic
eﬃciencies of the enzymes are several orders of magnitude
higher than the intrinsic eﬃciencies of the enzymes. Very large
amounts of thrombin are generated during the coagulation
process. Thrombin has multiple procoagulant functions, e.g.,
it activates FV and FVIII and platelets, it converts ﬁbrinogen
to a ﬁbrin clot, and it activates FXIII to an active transgluta-
minase that cross-links ﬁbrin (Fig. 1) [8,9].
Blood coagulation is controlled by several anticoagulant
principles and under normal conditions they prevail over the
procoagulant forces. A natural anticoagulant system denoted
the protein C pathway exerts its anticoagulant eﬀect by regu-
lating the activity of FVIIIa and FVa, the cofactors in the ten-
ase and prothrombinase complexes, respectively.
The vitamin K-dependent protein C is the key component of
the pathway [4,7,10–13]. It circulates as a proenzyme to an
anticoagulant serine protease and is activated by thrombin
(T) bound to the endothelial membrane protein thrombomod-
ulin (TM). Activated protein C (APC) cleaves and inhibits
coagulation cofactors FVIIIa and FVa, which result in down-
regulation of the activity of the coagulation system. The pro-
tein C pathway comprises multiple proteins involved in the
diﬀerent reactions (Fig. 1A). Thus, there are proteins aﬀecting
the activation of protein C by the T–TM complex, cofactor
proteins that modulate the proteolytic activity of APC and ser-
ine protease inhibitors that inactivates APC. The endothelial
protein C receptor (EPCR) stimulates the T–TM-mediated
activation of protein C on the endothelial cell surface
(Figs. 2A and 3A) [12,14]. The two cofactors, protein S and
the intact form of FV, enhance the anticoagulant activity of
APC. Protein S is suﬃcient for inactivation of FVa (Fig.
2B), whereas regulation of FVIIIa in the tenase complex re-
quires the synergistic contribution of protein S and FV [7].
Protein S is a vitamin K-dependent plasma protein, which in
human plasma to 60–70% is bound to the complement regula-
tor C4b-binding protein (C4BP) (Fig. 4). The free form of pro-
tein S function as APC cofactor, whereas the complexed form
does not [10,15–17]. Protease inhibitors such as the protein C
inhibitor (PCI), a1-antitrypsin, and a2-macroglobulin inhibitblished by Elsevier B.V. All rights reserved.
Fig. 1. Schematic representation of blood coagulation and the protein
C anticoagulant system. Section A demonstrates a scheme of blood
coagulation reactions together with the balancing anticoagulant
reactions of the protein C pathway. The coagulation scheme is
incomplete as the interaction between FVIIa and tissue factor (TF) and
the FVIIa–TF mediated activations of FIX and FX are not shown. In
section B, a schematic model of the prothrombinase complex is shown
to illustrate the principle of multi-molecular enzyme complexes
forming on the surface of negatively charged phospholipid membranes.
The enzyme FXa and the cofactor FVa assemble on the surface of
negatively charged phospholipid to form the prothrombinase complex,
which eﬃciently converts prothrombin to thrombin and fragment 1.2.
Fig. 2. Schematic model of certain reactions of the protein C
anticoagulant system. (A) Activation of protein C by thrombin bound
to thrombomodulin (TM). EPCR (endothelial protein C receptor)
binds the Gla-domain of protein C and helps orient protein C to the T–
TM complex. (B) Degradation of FVa by APC in the presence of
protein S, which serves as an APC cofactor. APC cleaves FV at three
sites, Arg306, Arg506 and Arg679, which results in dissociation of
degradation fragments from the FVa molecule and loss of FVa
activity.
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life of APC in circulation is 20 min [10,11].
Recently, protein C has been shown not only to express anti-
coagulant activities but also to function as an anti-inﬂamma-
tory and anti-apoptotic factor [12,18,19]. Moreover, APC
has been found to be useful as a therapeutic agent in the
treatment of sepsis, the unique combination of anticoagulant,
anti-inﬂammatory and anti-apoptotic properties of APC pre-
sumably being important [12,18,20–23]. Protein C and the
other components of the pathway have been intensively inves-
tigated and knowledge about the three-dimensional (3D) struc-
ture of the proteins has been gained. The intricate relationships
between the structures of the proteins and their functions are
in focus in this review.2. Activation of protein C on endothelium
Protein C is a vitamin K-dependent multi-domain protein
composed of a light and a heavy chain, the two chains being
disulﬁde-linked (Figs. 2 and 3). A vitamin K-dependent do-
main containing c-carboxy-glutamic acid (Gla) residues andtwo epidermal growth factor (EGF)-like domains occupy the
light chain. The heavy chain contains a short activation pep-
tide and a serine protease domain [10]. Vitamin K-dependent
post-translational carboxylation of glutamic acid residues gen-
erates the Gla residues. These residues are important for cal-
cium binding to the Gla-domain and for the proper folding
of the domain [24]. The correctly folded Gla-domain binds
negatively charged phospholipid membranes, which is impor-
tant for the anticoagulant activity of APC. The Gla-domain
can also bind the endothelial receptor EPCR, an interaction
that is important for both the activation of protein C and
the generation of anti-inﬂammatory and anti-apoptotic activi-
ties of APC (Figs. 2–4) [12,14]. The functions of the EGF do-
mains are not well understood but most likely they are
important for interaction with other proteins such as protein S,
FVa and FVIIIa. The activation peptide of protein C is
released during the activation by the T–TM–EPCR com-
plex, and the serine protease domain converted to its active
conformation.
TM is present in all vascular endothelium, the capillary bed
having particularly high concentration and a high surface area
to blood volume which favors thrombin binding and protein C
activation [12,25,26]. TM occupies the functionally important
exosite I in thrombin and thereby blocks interactions with
other thrombin-binding proteins (Figs. 2 and 3). The procoag-
ulant properties of thrombin are, therefore, lost upon binding
Fig. 3. 3D overview of the protein C activation and the FVa
degradation. (A) The ﬁgure illustrates the complex (determined by
X-ray crystallography) between thrombin (T) (solid surface magenta)
and EGFs 4–6 of thrombomodulin (TM) (ribbon in green, blue and
white, respectively) and a theoretical model of protein C (solid
surface). The Gla-domain of protein C is bound to EPCR (ribbon,
magenta). In EPCR, a phospholipid (green) is bound in a groove.
Some key loops of protein C denoted 37, 60, and 70 are coloured. The
white dashed lines indicate that the protein contains other domains.
The red line in TM running toward thrombin represents the
chondroitin sulfate side chain. AP, activation peptide approaching
the active site of thrombin (arrow); SP, serine protease domain. (B) A
theoretical model of human FVa and the X-ray structure of APC-
cleaved bovine FVa are shown. Two APC cleavage sites, R306 and
R506, in FVa are indicated. APC is docked at position R506 and
slightly moved apart to facilitate presentation of the ﬁgure. The loops
in APC that are important for the interaction (loops 37 and 148) are
blue. The A2-domain dissociates after cleavage at Arg306 and FVi
remains. For references and discussion please see the text.
Fig. 4. Schematic models of APC-mediated activation of PAR-1 and
protein S binding to apoptotic cells. (A) The Gla-domain of APC binds
EPCR and the active site of APC cleaves PAR-1 (protease-activated
receptor-1). The PAR-1 polypeptide spans the phospholipid membrane
seven times. The cytoplasmatic part of PAR-1 binds to G-proteins.
The cleavage of PAR-1 creates a novel N-terminus, which activates
PAR-1. This results in the activation of the intra-cellular G-proteins
and generation of anti-inﬂammatory and anti-apoptotic responses (see
text for references). (B) Negatively charged phosphatidylserine is
exposed on the surface of apoptotic cells. Free protein S and the
protein S–C4BP complex bind to the cell surface via the Gla-domain of
protein S. This provides the potential for regulation of both coagu-
lation and the complement systems on the surface of apoptotic cells. In
addition, the bound protein S stimulates phagocytosis of the apoptotic
cells [44]. The octopus-like shape of C4BP is illustrated, the arrows
indicating the a- and b-chains.
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thrombin (AT) and PCI eﬃciently inhibit the TM-bound
thrombin [11,12]. The multiple anticoagulant properties of
TM, i.e., the conversion of thrombin into an activator of pro-
tein C and the accelerated inhibition of thrombin, makes TM a
crucial regulator of blood coagulation. TM contains several
domains and the molecule is a type I membrane protein (Figs.
2A). The N-terminal type C lectin domain is followed by six
EGF domains, a Ser/Thr-rich region, a transmembrane section
and a short cytoplasmic tail [12,25,26]. The Ser/Thr-rich region
contains a chondroitin sulfate side chain that stimulates theAT- and PCI-mediated inhibition of thrombin that has bound
to TM. The EGF domains are important for the activation of
protein C. Thrombin binds to EGF5 and EGF6, whereas pro-
tein C interacts with EGF4 (Figs. 2 and 3). In this interaction,
a positively charged cluster, formed by basic amino acid resi-
dues in serine protease domain loops 37, 60, 70, and 148 (min-
or role), is important [11,12,25]. The activation of protein C is
augmented by EPCR which binds the Gla-domain of protein C
and aligns the substrate protein C with the activating T–TM
complex [12,14]. EPCR is a member of the MHC class
1/CD1 family and a type I membrane protein. It contains two
a-helices and an eight-stranded b-sheet that create a phospho-
lipid-binding groove. The phospholipid binding is important
for the ability of EPCR to bind the Gla-domain of protein C
(Fig. 3) [27].3. Inhibition of coagulation by APC and the role of cofactors
The membrane-bound FV/FVa and FVIIIa are substrates
for APC, which cleaves a few peptide bonds in each molecule.
FV and FVIII are homologous proteins sharing the domain
structure A1–A2–B–A3–C1–C2. The three A-domains are
arranged in a triangular fashion and the carbohydrate-rich
Fig. 5. Structures of the b-CCP1 of C4BP, protein S and APC. A
model of CCP1 (magenta) of the C4BP b-chain has been created and a
region rich in solvent exposed hydrophobic residues (in yellow) has
been demonstrated to play a crucial part in the interaction with protein
S [56]. Protein S is composed of several domains and theoretical
models for several regions have been reported, e.g., the region
comprising the Gla (yellow), the TSR (thrombin-sensitive region)
(blue) and EGF1 have been predicted. The structures of the other EGF
domains are unknown. The C-terminal region of protein S is composed
of two LamG-domains (green and white). The model was originally
predicted using the laminin X-ray structure and recently reﬁned using
the X-ray structure of Gas6 (unpublished data). The areas of the
LamG-domains that have been proposed as important for the
interaction with C4BP are shown in red on the protein S model [40].
Protein S is a cofactor for APC and a model of full length APC based
on a combination of the X-ray structure of the Gla-domain less APC
molecule is shown in order to help visualize the overall dimensions of
the system.
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[6,7,28,29]. The B-domains of both FV and FVIII are released
after cleavage by thrombin or FXa, the A1–A2–A3–C1–C2 do-
mains forming the active FVa and FVIIIa (Figs. 1–3). The
three A-domains are homologous to the three A-domains of
ceruloplasmin. The three-dimensional structure of ceruloplas-
min is known and forms the basis for theoretical molecular
models of the A-domains of FVa and FVIIIa [30,31]. The
structure of APC-cleaved bovine FVa lacking the A2-domain
is also determined as are structures for the C2-domains in
FV and FVIII [32–34]. It is interesting to note that the homol-
ogy-based models and the experimentally determined 3D
structures are in good agreement. For instance, based on the
human FVa model, we proposed which residues were involved
in calcium binding [30] and showed their importance by muta-
genesis [35]. The experimentally determined structure con-
ﬁrmed that the equivalent residues in bovine FVa were
indeed coordinating calcium [34]. In both FVIIIa and FVa,
the C2-domains contain the major phospholipid-binding sites
but a region of the C1-domain of FVa has based on mutagen-
esis studies also been suggested to be important for binding to
phospholipids. In FVIIIa and FVa, the high aﬃnity binding of
the respective cofactors, FIXa and FXa, involve the A2 and
A3-domains and the details of the interacting sites on partici-
pating proteins are beginning to emerge [28,29,36–38].
In FVa, three APC-cleavage sites have been identiﬁed at
positions Arg306, Arg506 and Arg679 (Figs. 2 and 3) [6,7].
The cleavages at the ﬁrst two sites demonstrate interesting dif-
ferences with regard to kinetics, requirement of APC cofactors,
and remaining activity after cleavage. The cleavage at Arg506
is less dependent on the presence of protein S and the phospho-
lipid composition than the Arg306 cleavage. Moreover, it is
kinetically favored over the Arg306 cleavage, is inhibited by
FXa bound to FVa, and only results in partial loss of FXa
cofactor activity [7]. In contrast, the Arg306 cleavage is fully
dependent on negatively charged phospholipid, not inhibited
by FXa bound to FVa, strongly stimulated by protein S and
results in severe loss of FVa activity. Total loss of FVa activity
is caused by the dissociation of the A2 fragments after cleavage
at Arg306 [39]. The diﬀerences in the cleavages at Arg306 and
Arg506 are due to diﬀerent involvement of an exosite in the SP
domain of APC in the two cleavages (Figs. 2B) [11,40]. A pos-
itively charged cluster in the SP domain of protein C formed
by basic residues in loops 60, 37, 70 and 148 (Figs. 2B and
3B) presumably interacts with a negatively charged region in
FVa located adjacent to the Arg506 site. Elimination of this
positive cluster by mutagenesis reduces the rate of cleavage
of the Arg506 site but has no eﬀect on the Arg306 site. The
same cluster in APC binds negatively charged heparin, which
at high concentrations speciﬁcally inhibits the APC-mediated
cleavage at Arg506.
The concentration of the tenase complex is much lower
than that of the prothrombinase complex as the FVIII con-
centration is 100-fold lower than that of FV [4]. This may
be the reason why in the APC-mediated regulation of the
tenase activity, not only protein S but also the non-activated
form of FV serve as cofactor to APC [7]. It has been shown
that the FV molecule is cleaved by APC at Arg306 and
Arg506 during the FVIIIa inactivation, at least the cleavage
at Arg506 being important for the ability of FV to serve as
APC cofactor in the reaction [7]. Moreover, the last section
of the B-domain of FV is important for the APC cofactoractivity of FV, as is an intact junction between the B-do-
main and the A3-domain. Upon full activation of FV by
thrombin, when the B–A3 junction is disrupted by the
thrombin-mediated cleavage at Arg1545, the anticoagulant
APC cofactor activity of FV is lost. Thus, FV is a Janus-
faced protein, having the ability to express both pro- and
anticoagulant functions depending on proteolysis by either
pro- or anticoagulant enzymes such as thrombin/FXa or
APC, respectively [7].4. Multiple functions of vitamin K-dependent protein S
Protein S contains several domains: an N-terminal vitamin
K-dependent Gla-domain, a thrombin-sensitive region
(TSR), four EGF-like domains and two laminin G-type
(LamG) domains (Figs. 2, 4, and 5) [10,15,16]. The Gla-do-
main has high aﬃnity for negative phospholipids and protein
S and APC form a membrane-bound complex, the Gla-do-
main, TSR, EGF1, and EGF2 being important for the interac-
tion [10,15,16,41]. Protein S has been suggested to decrease the
distance between the active site of APC and the phospholipid
membrane. This may be of importance for proper localization
of APC in relation to the cleavage sites in FVa and FVIIIa.
The LamG-domains are also important for the synergistic
function of protein S and FV during the APC-mediated degra-
dation of FVIIIa [10,15,16,40].
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ticular when calcium is present [10,15–17]. Both LamG-
domains of protein S are involved in the binding and several
areas in both LamG-domains have been suggested to contrib-
ute to the binding (Fig. 5). C4BP has an octopus-like structure
comprising seven a-chains and a single b-chain (Fig. 4) [17].
The chains are composed of CCP (complement control pro-
tein) domains arranged in tandem, eight in the a-chain and
three in the b-chain. Each a-chain binds a C4b molecule (acti-
vated complement protein C4) and converts it into a substrate
for factor I, a complement regulatory enzyme in blood. Thus,
C4BP is an important regulator of the classical complement
pathway. The b-chain CCP1 contains the binding site for pro-
tein S, a hydrophobic patch (I16, V18, V31 and I33) being par-
ticularly important (Fig. 5).
Negatively charged phosphatidylserine is under normal con-
ditions not exposedon the surface of cells but located in the inner
leaﬂet of the cellmembrane.Certain situations result in exposure
of phosphatidylserine on the cell surface, e.g., apoptosis or plate-
let activation. Protein S can bind to the negatively charged phos-
pholipids that are exposed on the surface of apoptotic cells and
on platelet microparticles [42,43]. The Gla-domain mediates the
binding, which is dependent on calcium. Protein S bound to the
apoptotic cell surface stimulates phagocytosis of the apoptotic
cells through mechanisms yet to be deﬁned [44]. The complex
protein S–C4BP also binds to the apoptotic cells but this is in
contrast found to counteract the phagocytic process [45]. Protein
S and the protein S–C4BP complex may have other important
functions on the apoptotic cell surface, e.g., controlling the coag-
ulation and complement pathways.
Protein S is homologous to the anti-apoptotic protein Gas6
(product of the growth arrest speciﬁc gene number 6), the two
proteins having similar domain organization. Gas6 is vitamin
K-dependent and as the name implies, the Gas6 synthesis is in-
duced by growth arrest, e.g., by serum starvation of cultured
cells [46–48]. Gas 6 has several biological eﬀects on cells,
e.g., it inhibits apoptosis, stimulates mitogenesis and growth.
Endothelium, ﬁbroblasts and smooth muscle cells express
Gas6, but in contrast to protein S, the liver does not express
it. Gas6 binds and stimulates tyrosine kinase receptors Axl,
Sky, and c-Mer [46–48]. The Gla-domain of Gas6 binds apop-
totic cells and stimulates phagocytosis. Protein S has also been
reported to function as a ligand for the Sky receptor. However,
the physiological signiﬁcance of this has been questioned be-
cause only protein S from certain species can stimulate the
Sky receptor [49].5. The protein C system and venous thrombosis
Individuals with complete inherited protein C deﬁciency suf-
fer from severe micro-vascular thrombotic disease (purpura
fulminans) already in the neonatal period [10,50]. This clearly
illustrates that the protein C system is vitally important to keep
the blood in a ﬂuid state and the circulatory system open. The
prevalence of protein C deﬁcient alleles is around 1/600 in the
population and, thus, complete deﬁciency occurs in
1/200 000–1/300 000 newborn and heterozygous deﬁciencies
in 1/300 [4]. Heterozygous protein C deﬁciency is associated
with 5-fold increased risk of venous thrombosis. Similar risk
of thrombosis aﬀects individuals with heterozygous protein Sdeﬁciency. The most common gene defect associated with ve-
nous thrombosis is the FV Leiden mutation (APC resistance),
which is present in 20–40% of thrombosis patients [4]. The FV
Leiden mutation (G1691A) replaces Arg506 with a Gln. The
protein C system is compromised in two ways by the FV Lei-
den mutation: (1) the degradation of mutant FVa by APC is
impaired because one of three APC cleavage sites is missing
in FVa Leiden; (2) the degradation of FVIIIa is poor because
FV Leiden cannot be cleaved at Arg506. Therefore, FV Leiden
is a poor cofactor to APC in the degradation of FVIIIa [7].
FV Leiden mutation, which is predominantly found in
whites, is 30 000 years old. The prevalence of FV Leiden in
the general population varies geographically. In America,
where the population is of mixed ethnic background the prev-
alence is 5% in the north and somewhat lower in the south.
In Europe there is a north to south gradient with highest prev-
alence (10–15%) in the north and lowest in the south (2%).
Individuals with heterozygous FV Leiden have 5-fold in-
creased risk of venous thrombosis, whereas homozygotes have
around 50-fold increased risk [4,51]. In contrast, FV Leiden is
not a risk factor for arterial thrombosis. The high prevalence
in certain populations suggests that the FV Leiden allele have
provided a survival advantage during evolution. In fact, even
today women with FV Leiden have reduced bleeding tendency
after delivery. In the history of mankind this must have been a
major survival beneﬁt.6. Anti-inﬂammatory and anti-apoptotic eﬀects of protein C
Components of the protein C pathway have biological eﬀects
other than those strictly referred to as being anticoagulant
[16,18,25,52]. However, the molecular mechanisms of these
activities and their physiological importance are not yet fully
understood. It has been found that the lectin domain of TM
has anti-inﬂammatory properties, down-regulating NF jB and
the MAP kinase pathways, and also decreases leukocyte adhe-
sion and extravasation [52]. TAFI (thrombin activatable
ﬁbrinolysis inhibitor), a carboxypeptidase B that removes C-
terminal lysine residues from ﬁbrin is activated by the T–TM
complex [25]. TAFI inhibits ﬁbrinolysis and inactivates the ana-
phylatoxins C3a and C5a. Both protein C and APC directly in-
hibit the adhesion of neutrophils to the endothelial cell surface
and the trans-migration of neutrophils. In addition, APChas di-
rect anti-inﬂammatory and anti-apoptotic properties that seem
to depend on the presence of both EPCR and protease-activated
receptor-1 (PAR-1) in the membrane (Fig. 4) [18,53]. PAR-1,
which is primarily cleaved by thrombin, is a seven-transmem-
brane domain, G-protein-coupled receptor. After cleavage, the
novel N-terminus of PAR-1 activates itself by an intra-cellular
signaling event. Recently, it was shown that thrombin is several
orders of magnitude (104) more potent than APC in cleaving
PAR-1, which raises doubts as to the physiological signiﬁcance
of the APC-mediated PAR-1 cleavage in vivo [54].7. The protein C system and the treatment of severe sepsis
Blood coagulation is activated during sepsis by, which is TF
expressed on the endothelium and monocytes/macrophages
in response to cytokines (e.g., TNF, IL-1 and IL- 6) [18,55].
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shock and the drop in the plasma level of protein C may con-
tribute to the development of micro-vascular thrombosis and
DIC (disseminated intravascular coagulation). In addition,
the expression levels of TM and EPCR on endothelium de-
crease during sepsis. APC can counteract the deleterious eﬀects
associated with sepsis. Thus, in a study of severe sepsis
(PROWESS) recombinant APC (drotrecogin alfa-Xigris) gave
a 19.4% reduction in the relative risk of death and an absolute
reduction of 6.1% [21]. Thus, the protein C system plays a role
in the defense against sepsis, the anticoagulant as well as anti-
inﬂammatory and anti-apoptotic properties of APC presum-
ably being crucial.8. Concluding remarks
The elucidation of the molecular mechanisms of the intricate
protein C system has not only provided insights into a fascinat-
ing molecular world but also knowledge of great medical rele-
vance. Insights have been gained in the structure–function
relationships of macromolecular complexes important for the
activation of protein C, the regulation of tenase and prothrom-
binase complexes, and the cell–surface interactions with EPCR/
PAR-1. Many unanswered questions remain and some are par-
ticularly challenging, e.g., the molecular mechanism of the syn-
ergistic APC cofactor activity of FV and protein S that regulates
FVIIIa in the tenase complex and elucidation of the cell–surface
and intra-cellular events associated with the anti-inﬂammatory
and anti-apoptotic functions of the protein C system.References
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